Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | BCR | P11274 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.33 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.33 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.33 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.33 |
| ▸ | KDR | P35968 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TNF | P01375 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL314835 | 1.00 | ABL1 (0.35) | ABL1BCRFGFR1FGFR2FGFR4 | |
| SCHEMBL2410894 | 0.80 | HTR7 (0.40) | POLBFFAR1 | |
| SCHEMBL314211 | 0.80 | BRD4 (0.36) | POLBFFAR1 | |
| SCHEMBL314212 | 0.80 | BRD4 (0.36) | POLBFFAR1 | |
| SCHEMBL2410899 | 0.80 | HTR7 (0.40) | POLBFFAR1 | |
| SCHEMBL314939 | 0.79 | MAPK1 (0.34) | ABL1CHRNA7 | |
| SCHEMBL315465 | 0.79 | AURKA (0.35) | — | |
| SCHEMBL315464 | 0.79 | AURKA (0.35) | — | |
| SCHEMBL314940 | 0.79 | MAPK1 (0.34) | ABL1CHRNA7 | |
| SCHEMBL2140812 | 0.78 | CHRNA7 (0.47) | ABL1CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093394-B2 | Derivatives of 5-thioxylopyranose and use of same for treatment | LABORATOIRES FOURNIER S.A. (FR) | 2012-01-10 | — | — | US | disclosed |
| EP-2066683-B1 | DERIVATIVES OF 5-THIOXYLOPYRANOSE AND USE OF SAME FOR TREATMENT | FOURNIER LAB SA (FR) | 2010-11-03 | — | — | EP | disclosed |
| US-20090182013-A1 | Derivatives of 5-Thioxylopyranose and Use of Same for Treatment | LABORATOIRES FOURNIER S.A. (FR) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182013-A1 | Derivatives of 5-Thioxylopyranose and Use of Same for Treatment | TPMT, PNPO, PPOX | ABL1 1574/4885BCR 3624/4885FGFR1 3476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.